Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Queensland Health
US Army
Daiichi Sankyo
QuintilesIMS
AstraZeneca

Generated: June 26, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GRANISETRON HYDROCHLORIDE

Try a free trialSee Plans and Pricing

« Back to Dashboard

Clinical Trials for Granisetron Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00003213 Drugs to Reduce the Side Effects of Chemotherapy Completed Swiss Group for Clinical Cancer Research Phase 3 RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients treated with chemotherapy. It is not known whether receiving dexamethasone with granisetron is more effective than receiving dexamethasone with metoclopramide for reducing the side effects of chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of dexamethasone with either granisetron or metoclopramide in patients treated with chemotherapy.
NCT00004219 Lerisetron Compared With Granisetron in Preventing Nausea and Vomiting in Men Being Treated With Radiation Therapy for Stage I Seminoma Unknown status Simbec Research Phase 3 RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients treated with radiation therapy. It is not yet known whether lerisetron is more effective than granisetron in preventing nausea and vomiting. PURPOSE: Randomized phase III trial to compare the effectiveness of lerisetron with that of granisetron in preventing nausea and vomiting in men who are being treated with radiation therapy for stage I seminoma.
NCT00005024 Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease Unknown status National Cancer Institute (NCI) Phase 3 RATIONALE: Antiemetic drugs such as granisetron may help to prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of granisetron with that of a placebo in preventing nausea and vomiting after chemotherapy in patients who have malignant disease.
NCT00005024 Granisetron to Prevent Nausea and Vomiting After Chemotherapy in Patients With Malignant Disease Unknown status Jonsson Comprehensive Cancer Center Phase 3 RATIONALE: Antiemetic drugs such as granisetron may help to prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of granisetron with that of a placebo in preventing nausea and vomiting after chemotherapy in patients who have malignant disease.
NCT00020657 Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer Completed National Cancer Institute (NCI) Phase 3 RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in preventing delayed nausea after chemotherapy in patients who have cancer.
NCT00020657 Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer Completed Gary Morrow Phase 3 RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in preventing delayed nausea after chemotherapy in patients who have cancer.
NCT00146042 UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer Completed Genentech, Inc. Phase 2 This is a research study which aims to improve the way that doctors determine the dose of chemotherapy given to patients. Right now, chemotherapy is determined by a patient's height and weight. However, some patients metabolize chemotherapy faster or slower than the average person because of a different level of drug metabolizing enzyme in the liver. Therefore, some patients are either given too small or too large a dose of chemotherapy because the amount of enzyme is not taken into account. This research study will examine the use of a simple test, call the Erythromycin Breath Test(ERMBT) to determine the amount of enzyme which can metabolize the chemotherapy drug docetaxel (Taxotere). The dose of docetaxel will be tailored to the amount of enzyme which is available to metabolize the drug for each patient. The drug, docetaxel, is combined with another drug, trastuzumab (Herceptin), because at this time this combination appears to be promising in metastatic breast cancer research.
Trial ID Title Status Sponsor Phase Summary

Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Granisetron Hydrochloride

Condition Name

Condition Name for Granisetron Hydrochloride
Intervention Trials
Nausea 11
Vomiting 10
Chemotherapy-Induced Nausea and Vomiting 9
Nausea and Vomiting 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Granisetron Hydrochloride
Intervention Trials
Vomiting 43
Nausea 39
Postoperative Nausea and Vomiting 10
Breast Neoplasms 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Granisetron Hydrochloride

Trials by Country

Trials by Country for Granisetron Hydrochloride
Location Trials
United States 96
China 11
Canada 7
Korea, Republic of 5
Taiwan 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Granisetron Hydrochloride
Location Trials
Michigan 7
Illinois 6
Wisconsin 5
Massachusetts 5
North Carolina 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Granisetron Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Granisetron Hydrochloride
Clinical Trial Phase Trials
Phase 4 14
Phase 3 22
Phase 2/Phase 3 1
[disabled in preview] 51
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Granisetron Hydrochloride
Clinical Trial Phase Trials
Completed 50
Recruiting 12
Unknown status 10
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Granisetron Hydrochloride

Sponsor Name

Sponsor Name for Granisetron Hydrochloride
Sponsor Trials
Prostrakan Pharmaceuticals 9
National Cancer Institute (NCI) 7
Merck Sharp & Dohme Corp. 6
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Granisetron Hydrochloride
Sponsor Trials
Other 75
Industry 46
NIH 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Covington
Chinese Patent Office
US Army
Deloitte
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.